Daniel Drucker, a clinician-scientist at the Lunenfeld-Tanenbaum Research Institute at Toronto's Mount Sinai Hospital who helped lay the foundation for these drugs, called the study a powerful analysis
Clinical Evidence Supporting Semaglutide in PCOS Management Randomized controlled trials have demonstrated that GLP-1 receptor agonists improve insulin sensitivity (measured by HOMA-IR scores) in PCOS populations by 2035%, independent of weight loss alone
Some users have reported dizziness, fatigue, headache, or nausea, particularly when first starting treatment
Now theres talk of an oral form (more than 70 versions are in the pipeline ) and uses in treating dementia, arthritis, and sleep apnea
While very safe, they are generally insufficient as monotherapy for semaglutide-related constipation
Clinicians must, therefore, extrapolate from established principles for GLP-1 switching namely, avoiding direct dose equivalence and prioritising patient safety as per individual drug summary of product characteristics